区分酿酒酵母益生菌株和临床菌株的分子工具。
Molecular tools for differentiating probiotic and clinical strains of Saccharomyces cerevisiae.
作者信息
Posteraro Brunella, Sanguinetti Maurizio, Romano Lucio, Torelli Riccardo, Novarese Linda, Fadda Giovanni
机构信息
Istituto di Microbiologia, Università Cattolica del Sacro Cuore, Largo F. Vito, 1-00168 Rome, Italy.
出版信息
Int J Food Microbiol. 2005 Sep 15;103(3):295-304. doi: 10.1016/j.ijfoodmicro.2004.12.031.
The subtype of the Saccharomyces cerevisiae yeast species known as S. cerevisiae Hansen CBS 5926 was formerly believed to be a separate species, Saccharomyces boulardii. It is widely considered non-pathogenic and is used as a probiotic agent for treatment and prevention of diarrhea. The biological properties of Saccharomyces spp. show considerable intraspecies variability and the beneficial properties of probiotic yeasts are considered strain-specific. Septicemia and fungemia caused by S. boulardii have recently been described in both immunocompromised and immunocompetent patients receiving biotherapy with this yeast. It cannot be distinguished from other S. cerevisiae strains by phenotypic criteria, so identification of these infections requires molecular typing. To identify the most effective approach for distinguishing S. boulardii, we typed 35 isolates of S. cerevisiae, of which 27 were from various clinical specimens and 8 were isolates of S. boulardii (6 obtained from probiotic preparations and 2 from clinical specimens) using four different molecular methods, two based on PCR-restriction enzyme analysis or sequencing of rDNA spacer regions, the third based on microsatellite polymorphism analysis of the S. cerevisiae genes YKL139w and YLR177w, and the last based on hybridization analysis with retrotransposon Ty917. Several clinical isolates appeared to be identical to one or more other isolates with the first three methods used, whereas with the Ty917 hybridization method all of the isolates tested appeared to be very heterogeneous. The eight S. boulardii isolates were clearly distinguishable from the clinical S. cerevisiae isolates only with Ty917 hybridization and microsatellite DNA analyses. In the latter method, the eight S. boulardii isolates exhibited an allelic variant at one of loci tested that was not shared with any other strain. Our results suggest that microsatellite polymorphism analysis of the YKL139w and YLR177w genes, as well as the analysis by Ty917 hybridization, are the most useful tools for a correct identification of S. boulardii strains.
酿酒酵母(Saccharomyces cerevisiae)的亚型,即酿酒酵母汉森CBS 5926,以前被认为是一个独立的物种——布拉氏酵母菌(Saccharomyces boulardii)。它被广泛认为是非致病性的,并被用作治疗和预防腹泻的益生菌剂。酿酒酵母属(Saccharomyces spp.)的生物学特性表现出相当大的种内变异性,益生菌酵母的有益特性被认为是菌株特异性的。最近,在接受这种酵母生物疗法的免疫功能低下和免疫功能正常的患者中,均有布拉氏酵母菌引起的败血症和真菌血症的报道。通过表型标准无法将其与其他酿酒酵母菌株区分开来,因此这些感染的鉴定需要分子分型。为了确定区分布拉氏酵母菌的最有效方法,我们使用四种不同的分子方法对35株酿酒酵母进行了分型,其中27株来自各种临床标本,8株是布拉氏酵母菌分离株(6株来自益生菌制剂,2株来自临床标本),两种方法基于PCR-限制性酶切分析或rDNA间隔区测序,第三种方法基于酿酒酵母基因YKL139w和YLR177w的微卫星多态性分析,最后一种方法基于与反转录转座子Ty917的杂交分析。使用前三种方法时,几个临床分离株似乎与一个或多个其他分离株相同,而使用Ty917杂交方法时,所有测试的分离株似乎都非常异质。仅通过Ty917杂交和微卫星DNA分析,八个布拉氏酵母菌分离株就能与临床酿酒酵母分离株明显区分开来。在后一种方法中,八个布拉氏酵母菌分离株在一个测试位点上表现出一个等位基因变体,该变体与任何其他菌株都不相同。我们的结果表明,YKL139w和YLR177w基因的微卫星多态性分析以及Ty917杂交分析是正确鉴定布拉氏酵母菌菌株的最有用工具。